Mandatory Metabolic Syndrome Check In Japan Provides Opportunities For Pharma Companies
This article was originally published in PharmAsia News
Executive Summary
Starting this April, Japanese health insurers will be required to provide annual health checks to beneficiaries 40-74 years old in an effort to reduce the number of metabolic syndrome patients. Pharmaceutical companies such as Novartis, Novo Nordisk and Pfizer have leveraged this new requirement to launch various public relations campaigns. Novartis Japan has sponsored a campaign to raise public awareness of hypertension. Novartis cites that among 350 million hypertension patients in Japan, only 7.8 million are receiving treatment. Danish company Novo Nordisk, the world's top insulin drug maker, has conducted a survey on lifestyle diseases among working Japanese ages 30 to 40, and found that on average 32 is the age for people to have the tendency of becoming overweight. And with an April launch of a smoking cessation drug, Pfizer has banned employee smoking inside the company as a measure to prevent smoking caused lifestyle diseases. (Click here for more-Japanese language
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.